Mostrar el registro sencillo del ítem

Updates on the production of therapeutic antibodies using human hybridoma technique

dc.contributor.authorGlukhova X.A.
dc.contributor.authorPrusakova O.V.
dc.contributor.authorTrizna J.A.
dc.contributor.authorZaripov M.M.
dc.contributor.authorAfanas’Eva G.V.
dc.contributor.authorGlukhov A.S.
dc.contributor.authorPoltavtseva R.A.
dc.contributor.authorIvanov A.A.
dc.contributor.authorAvila-Rodriguez M.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAliev G.
dc.contributor.authorBeletsky I.P.
dc.date.accessioned2020-09-02T22:19:17Z
dc.date.available2020-09-02T22:19:17Z
dc.date.issued2016
dc.identifier10.2174/1381612822666151223102845
dc.identifier.citation22, 7, 870-878
dc.identifier.issn13816128
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4685
dc.descriptionTherapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies. © 2016 Bentham Science Publishers.
dc.language.isoen
dc.publisherBentham Science Publishers
dc.subjectB cells
dc.subjectEbv transformation
dc.subjectFusion partner
dc.subjectHybridoma
dc.subjectMir transformation
dc.subjectTherapeutic antibodies
dc.subjectcytokine
dc.subjectmonoclonal antibody
dc.subjectmonoclonal antibody
dc.subjectantibody engineering
dc.subjectantigen specificity
dc.subjectArticle
dc.subjectB lymphocyte
dc.subjectcell hybridization
dc.subjectDNA modification
dc.subjectEpstein Barr virus
dc.subjecthuman
dc.subjecthuman hybridoma technology
dc.subjecthybridoma
dc.subjectin vitro propagation
dc.subjectlymphocyte
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjecttransgenic mouse
dc.subjectanimal
dc.subjectdrug design
dc.subjecthybridoma
dc.subjectimmunology
dc.subjectmedical technology
dc.subjectmouse
dc.subjectprocedures
dc.subjectAnimals
dc.subjectAntibodies, Monoclonal
dc.subjectBiomedical Technology
dc.subjectDrug Design
dc.subjectHumans
dc.subjectHybridomas
dc.subjectMice
dc.subjectMice, Transgenic
dc.titleUpdates on the production of therapeutic antibodies using human hybridoma technique
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84958559512.pdf
Tamaño:
3.173Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem